成人型非免疫规划疫苗延迟接种安全性和有效性分析及接种建议

白云骅; 王琳; 郑东旖; 张丽丽; 石鑫淼; 王晓燕; 芦强; 刘瑶瑶; 李倩; 李淑萍; 张政; 刘兆秋; 谭美珍

doi:10.16462/j.cnki.zhjbkz.2020.08.021

文章导航 > 中华疾病控制杂志 > 2020 > 24(8): 971-976

白云骅, 王琳, 郑东旖, 张丽丽, 石鑫淼, 王晓燕, 芦强, 刘瑶瑶, 李倩, 李淑萍, 张政, 刘兆秋, 谭美珍. 成人型非免疫规划疫苗延迟接种安全性和有效性分析及接种建议[J]. 中华疾病控制杂志, 2020, 24(8): 971-976. doi: 10.16462/j.cnki.zhjbkz.2020.08.021

引用本文:

BAI Yun-hua, WANG Lin, ZHENG Dong-yi, ZHANG Li-li, SHI Xin-miao, WANG Xiao-yan, LU Qiang, LIU Yao-yao, LI Qian, LI Shu-ping, ZHANG Zhen, LIU Zhao-qiu, TAN Mei-zhen. Analysis and recommendation for the Non-Expanded Program on Immunization vaccines based on the immunogenicity and safety data[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2020, 24(8): 971-976. doi: 10.16462/j.cnki.zhjbkz.2020.08.021

Citation:

BAI Yun-hua, WANG Lin, ZHENG Dong-yi, ZHANG Li-li, SHI Xin-miao, WANG Xiao-yan, LU Qiang, LIU Yao-yao, LI Qian, LI Shu-ping, ZHANG Zhen, LIU Zhao-qiu, TAN Mei-zhen. Analysis and recommendation for the Non-Expanded Program on Immunization vaccines based on the immunogenicity and safety data[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2020, 24(8): 971-976. doi: 10.16462/j.cnki.zhjbkz.2020.08.021

引用本文:

Citation:

BAI Yun-hua, WANG Lin, ZHENG Dong-yi, ZHANG Li-li, SHI Xin-miao, WANG Xiao-yan, LU Qiang, LIU Yao-yao, LI Qian, LI Shu-ping, ZHANG Zhen, LIU Zhao-qiu, TAN Mei-zhen. Analysis and recommendation for the Non-Expanded Program on Immunization vaccines based on the immunogenicity and safety data[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2020, 24(8): 971-976. doi: 10.16462/j.cnki.zhjbkz.2020.08.021

成人型非免疫规划疫苗延迟接种安全性和有效性分析及接种建议

doi: 10.16462/j.cnki.zhjbkz.2020.08.021

1.
100021 北京, 北京市朝阳区疾病预防控制中心生物制品科
2.
100020 北京, 首都儿科研究所附属儿童医院儿童保健科
3.
100016 北京, 清华大学第一附属医院保健科
4.
510120 广东, 广州市妇女儿童医疗中心儿童保健科

详细信息

通讯作者:
白云骅, E-mail:13651367636@126.com

中图分类号: R186
计量
- 文章访问数: 316
- HTML全文浏览量: 291
- PDF下载量: 40
- 被引次数: 0
出版历程
- 收稿日期: 2020-03-11
- 修回日期: 2020-05-25
- 刊出日期: 2020-08-10

Analysis and recommendation for the Non-Expanded Program on Immunization vaccines based on the immunogenicity and safety data

1.
Beijing Chaoyang District Center for Disease Control and Prevention, Beijing 100021, China
2.
Children's Hospital, Capital Institute of Pediatrics, Beijing 100020, China
3.
the First Affiliated Hospital of Tsinghua University, Beijing 100016, China
4.
Guangzhou Women and Children Medical Center, Guangdong 510120, China

More Information

Corresponding author: BAI Yun-hua, E-mail:13651367636@126.com

摘要

摘要: 处理好疫苗安全接种和延迟接种之间的关系，是当前预防接种工作的重点和难点。现就中国常用成人型非免疫规划疫苗延迟接种进行安全性和有效性分析，同时做出具体接种建议，以期更好的对该类疫苗科学使用和发挥预防作用提供循证依据。
- 非免疫规划疫苗 /
- 延迟接种 /
- 安全性 /
- 免疫原性 /
- 成人
Abstract: How to guarantee the safety and delay of the vaccination is our key focus in the present vaccination work. In this paper, we made specific vaccination suggestions through analysis on the safety and effectiveness of delayed vaccinations for commonly used Non-Expanded Program on/Immunization vaccines in adults in China, in order to provide evidence for the scientific use and play the preventive role of the vaccine.
- Non-Expanded Program on Immunization vaccine /
- Delayed vaccination /
- Safety /
- Immunogenicity /
- Adult

HTML全文

参考文献(37)

[1]	Wang C, Horby PW, Hayden FG, et al. A novel coronavirus outbreak of global health concern[J]. Lancet, 2020, 395(10223):470-473. DOI: 10.1016/S0140-6736(20)30185-89.
[2]	中华预防医学会, 中华预防医学会疫苗与免疫分会.新型冠状病毒肺炎流行期间预防接种参考指引(第一版)[EB/OL]. (2020)[2020-03-01]. https://mp.weixin.qq.com/s/nisLTWiD8SnSORLZ3hwOBg. Chinese preventive medicine association, vaccine and immunization branch of Chinese preventive medicine association. Guide for vaccination during novel coronavirus (1st edition)[EB/OL]. (2020)[2020-03-01]. https://mp.weixin.qq.com/s/nisLTWiD8SnSORLZ3hwOBg.
[3]	北京市疾病预防控制中心.新型冠状病毒感染的肺炎流行期间儿童预防接种防控指引(第一版)[EB/OL]. (2020-01-30)[2020-03-01]. http://www.bjcdc.org/article/ztbd/2020/2/4028a8db6fbbc3bd016ff68648c80636.html. Beijing center for disease control and prevention. Guide for infant vaccination during novel coronavirus (1st edition)[EB/OL]. (2020-01-30)[2020-03-01]. http://www.bjcdc.org/article/ztbd/2020/2/4028a8db6fbbc3bd016ff68648c80636.html.
[4]	王琳, 白云骅, 方拴锋, 等.新型冠状病毒肺炎流行期间疫苗延迟接种安全性和有效性分析及接种建议(第一版)[J].中国儿童保健杂志, 2020, 28(3):242-246. DOI: 10.11852/zgetbjzz2020-0143. Wang L, Bai YH, Fang SF, et al. Immunogenicity and safety analysis and recommendations for infant vaccination delay (1st edition)[J]. Chin J Child Heal Care, 2020, 28(3):242-246. DOI: 10.11852/zgetbjzz2020-0143.
[5]	中华预防医学会儿童保健分会.新型冠状病毒肺炎流行期间非免疫规划疫苗延迟接种安全性和有效性分析及建议[J].中华儿科杂志, 2020, 58(4): 263-268. DOI: 10.3760/cma.j.cn112140-20200217-00097 Society of Child Health, Chinese Preventive Medicine Association. Recommendations for delayed immunization with non-national immunization program vaccines based on safety and efficacy analyses during the epidemic of COVID-19 in China[J]. Chin J Pediatr, 2020, 58(4): 263-268. DOI: 10.3760/cma.j.cn112140-20200217-00097
[6]	国家卫生和计划生育委员会.狂犬病暴露预防处置工作规范(2009年版)[S]. 2009-12-11. National Health and Family Planning Commission. Rules for Rabies exposure prevention and disposal (2009 edition).[S]. 2019-12-11.
[7]	中国疾病预防控制中心.狂犬病预防控制技术指南(2016版)[S]. 2016-1-29. China center for disease control and prevention. Technical guide for Rabies control and prevention (2016 edition)[S]. 2016-1-29.
[8]	World Health Organization. Rabies vaccine: WHO position paper[EB/OL]. (2018)[2020-03-01]. https://www.who.int/immunization/policy/position_papers/pp_rabies_2018_ZH.pdf?ua=1.
[9]	李晓梅, 周涛, 卢莉.北京市狂犬病暴露预防处置技术指南(试行)[J].首都公共卫生, 2018, 12(3):113-119. DOI: 10.16760/j.cnki.sdggws.2018.03.001. Li XM, Zhou T, Lu L. Technical guide for Rabies control and prevention in Beijing (Trial edition)[J]. Capital Journal of Public Health, 2018, 12(3):113-119. DOI: 10.16760/j.cnki.sdggws.2018.03.001.
[10]	WHO.WHO expert consultation on rabies[R]. Geneva: WHO, 2013.
[11]	Khawplod P, Wilde H, Chomchey P, et al. What is an acceptable delay in rabies immune globulin administration when vaccine alone had been given previously?[J]. Vaccine, 1996, 14(5):389-391. DOI: 10.1016/0264-410x(95)00213-k.
[12]	非新生儿破伤风诊疗规范(2019年版)编写审定专家组, 伤后破伤风疫苗和被动免疫制剂使用指南(2019年版)编写审定专家组.非新生儿破伤风诊疗规范(2019年版)[J].中华急诊医学杂志, 2019, (12): 1470-1475. DOI: 10.3760/cma.j.issn.1671-0282.2019.12.003 Expert group for preparation and approval of diagnostic and treatment specifications for non neonatal tetanus (2019 version), Expert group for the preparation and approval of guidelines for the use of tetanus vaccine and passive immune preparation (2019 version).Standard for diagnosis and treatment of non neonatal tetanus (2019 version)[J].Chin J Emerg Med, 2019, (12): 1470-1475. DOI: 10.3760/cma.j.issn.1671-0282.2019.12.003
[13]	董胜利, 孙莲英, 吴多琳, 等.育龄期妇女接种破伤风类毒素血清学效果初步研究[J].中国计划免疫, 2000, 6(3):140-144. DOI: 10.3969/j.issn.1006-916X.2000.03.005. Dong SL, Sun LY, Wu DL, et al. The primary immunogenicity research for tetanus toxoidvaccination in childbearing women.[J] Chin J Vaccine Immunizaiton, 2000, 6(3):140-144. DOI: 10.3969/j.issn.1006-916X.2000.03.005.
[14]	王传林, 刘斯, 尹遵栋, 等.外伤后破伤风疫苗和被动免疫制剂使用指南[J].中国疫苗和免疫, 2020, 26(1):111-115, 127. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgjhmy202001023 Wang CL, Liu S, Yin ZD, et al. Guidelines for post-traumatic use of tetanus vaccines and passive immune preparations[J]. Chinese Journal of Vaccines and Immuzization, 2020, 26(1):111-115, 127. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgjhmy202001023
[15]	陈清, 俞守义, 王雅贤, 等.冻干口服霍乱rBS-WC菌苗安全性及免疫原性的人群试验[J].中华预防医学杂志, 1996, 30(6):330-333. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhyfyx199606104 Chen Q, Yu SY, Wang YX, et al. Immunogenicity and safety evaluation for oral-administered lyophilized rBS-WC cholera vaccine.[J] Chin J Prev Med, 1996, 30(6):330-333. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhyfyx199606104
[16]	甄蓓, 俞守义, 陈清, 等.冻干口服霍乱rBS-WC疫苗现场试验及评价[J].中国计划免疫, 1999, 5(4):210-214. http://d.wanfangdata.com.cn/Periodical_lxyxkx200302009.aspx Zhen P, Yu SY, Chen Q, et al. Field trail and evaluation of oral-administered lyophilized rBS-WC cholera vaccine(capsule)[J]. Chin J Vaccine Immunizaiton, 1999, 5(4):210-214. http://d.wanfangdata.com.cn/Periodical_lxyxkx200302009.aspx
[17]	贾蕾, 吴疆, 赵伟, 等.口服霍乱菌苗安全性评价[J].现代预防医学, 2007, 34(1):128-130. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=xdyfyx200701062 Jia L, Wu J, Zhao W, et al. The safety evaluation of oral Cholera vaccine[J]. Modern Prevent Med, 2007, 34(1):128-130. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=xdyfyx200701062
[18]	吴辉绪. O139霍乱冻干口服疫苗(rBS-WC)的现场试验及评价[D].广州: 中国人民解放军第一军医大学, 2003. Wu HX. Field trail and evaluation of oral-administered lyophilized rBS-WC Cholera vaccine (rBS-WC)[D]. Guangzhou: The First Military Medical University, 2003.
[19]	World Health Organization. Cholera Vaccine: WHO position paper[EB/OL]. (2010)[2020-03-01]. https://www.who.int/immunization/documents/WHO_position_paper_cholera_vaccines_zh.pdf?ua=1.
[20]	Esposito S, Birlutiu V, Jarcuska P, et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine administered according to an alternative dosing schedule compared with the standard dosing schedule in healthy women aged 15 to 25 years:results from a randomized study[J]. Pediatr Infect Dis J, 2011, 30(3):e49-55. DOI: 10.1097/INF.0b013e318206c26e.
[21]	Neuzil KM, Canh DG, Thiem VD, et al. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in vietnam a cluster randomized noninferiority trial[J]. JAMA, 2011, 305(14):1424-1431. DOI: 10.1001/jama.2011.407.
[22]	陈直平, 孙晓冬, 王华庆, 等.人乳头瘤病毒疫苗在成年女性应用中的若干问题及建议[J].中华预防医学杂志, 2018, 52(9):879-884. DOI: 10.3760/cma.j.issn.0253-9624.2018.09.003. Chen ZP, Sun XD, Wang HQ, et, al. Discussion of f human papillomavirus vaccine administered in adult female.[J] Chin J Prev Med, 2018, 52(9):879-884. DOI: 10.3760/cma.j.issn.0253-9624.2018.09.003.
[23]	World Health Organization. Human papillomavirus vaccines: WHO position paper[EB/OL]. (2017)[2020-03-01].https://apps.who.int/iris/bitstream/handle/10665/255353/WER9219.pdf;jsessionid=29C893E3B98BD9AC037A8878B6F5A435?sequence=1.
[24]	Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination-updated recommendations of the Advisory Committee on Immunization Practices[J]. MMWR Morb Mortal Wkly Rep, 2016, 65(49):1405-1408. DOI: 10.15585/mmwr.mm6549a5.
[25]	Markowitz LE, Dunne EF, Saraiya M, et al. Human papillomavirus vaccination:recommendations of the Advisory Committee on Immunization Practices (ACIP)[J]. MMWR Recomm Rep, 2014, 63(RR-05):1-30.
[26]	Jilg W, Schmidt M, Deinhardt F. Vaccination against hepatitis B:comparison of three different vaccination schedules[J]. J Infect Dis, 1989, 160(5):766-769. DOI: 10.1093/infdis/160.5.766.
[27]	Jackson Y, Chappuis F, Mezger N, et al. High immunogenicity of delayed third dose of hepatitis B vaccine in travelers[J]. Vaccine, 2007, 25(17):3482-3484. DOI: 10.1016/j.vaccine.2006.12.053.
[28]	Wang ZZ, Gao YH, Wang P, et al. Comparison of immunogenicity between hepatitis B vaccines with different dosages and schedules among healthy young adults in China:a 2-year follow-up study[J]. Hum Vaccin Immunother, 2018, 14(6):1475-1482. DOI: 10.1080/21645515.2018.1438090.
[29]	Zhang J, Zhang XF, Huang SJ, et al. Long-term efficacy of a hepatitis E vaccine[J]. N Engl J Med, 2015, 372(10):914-922.DOI: 10.1056/NEJMoa1406011.
[30]	Schmidtke P, Habermehl P, Knuf M, et al. Cell mediated and antibody immune response to inactivated hepatitis A vaccine[J]. Vaccine, 2005, 23(44):5127-5132.DOI: 10.1016/j.vaccine.2005.06.022.
[31]	Iwarson S, Lindh M, Widerström L, et al. Excellent booster response 4 to 8 years after a single primary dose of an inactivated hepatitis A vaccine[J]. J Travel Med, 2004, 11(2):120-121.DOI: 10.2310/7060.2004.17079.
[32]	Hatz C, Van der Ploeg R, Beck BR, et al. Successful memory response following a booster dose with a virosome-formulated hepatitis a vaccine delayed up to 11 years[J]. Clin Vaccine Immunol, 2011, 18(5):885-887.DOI: 10.1128/CVI.00358-10.
[33]	北京市卫生局.北京市甲型肝炎疫苗免疫工作管理规程[S]. 2007. Beijing Municipal Health Bureau. Rule of hepatitis A vaccination management in Beijing[S]. 2007.
[34]	Ciprero K, Zykov KA, Briko NI, et al. Safety and immunogenicity of a single dose 23-valent pneumococcal polysaccharide vaccine in Russian subjects[J]. Hum Vaccin Immunother, 2016, 12(8):2142-2147. DOI: 10.1080/21645515.2016.1165373.
[35]	Hammitt LL, Bulkow LR, Singleton RJ, et al. Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55-74 years living in Alaska:no evidence of hyporesponsiveness[J]. Vaccine, 2011, 29(12):2287-2295. DOI:10.1016/j.vaccine. 2011.01.029.
[36]	Lal H, Poder A, Campora L, et al. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults:results of a phase Ⅲ, randomized, open-label, multicenter study[J]. Vaccine, 2018, 36(1):148-154. DOI: 10.1016/j.vaccine.2017.11.019.
[37]	Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster:recommendations of the Advisory Committee on Immunization Practices (ACIP)[J]. MMWR Recomm Rep, 2008, 57(RR-5):1-30. http://cid.oxfordjournals.org/external-ref?access_num=18528318&link_type=MED